simpliPlex MCBC-10plex

molecular classification of breast cancer test (MCBC-10plex)

Quick, easy and cost-effective
Uses minimal sample input
High performance and ultra sensitive
very versatile protocol
streamlined for various sample types
provides a digital output
quantitative output
assay is scalable to meet your needs
uses xMAP technology (Luminex)
RNA bead-based assay based on Invitrogen™ QuantiGene™ Plex gene expression assay (Thermo Fisher Scientific)

PREVENT DISEASE ....................EARLY DETECTION

PREDICT THERAPY OUTCOME ....CLASSIFY TUMOUR

PERSONALISE TREATMENT.........MONITOR PATIENT

Research & Development

simpliPlex R&D

Multiplex assays to measure tumour markers in blood are being developed. Register below to get updates on NEW products.

Innovative tests

Omnigene Medical Technologies contributes to global COVID-19 research. Vaccine surveillance test is under development.

Patient Care

Omnigene Medical Technology promotes emerging technologies to support health care and personalised medicine.

Molecular profiling multiplex assays enhance accuracy and precision of classification and surveillance of tumours

Multiplex assays enable the measurement of multiple analytes in low input samples, including tumour biopsies and circulating tumour derived cells, exosomes, cell-free DNA (cfDNA) and other molecules. Molecular classification of primary tissue, tumour heterogeneity, metastatic tissue, and early detection of therapy resistance requires the development of sensitive and precise multiplex assays with a streamlined and robust workflow.

NEWS

Researchers are measuring COVID-19 antibodies in Maltese patients

A University of Malta study measuring the antibodies generated by COVID-19 patients has secured €658,972 in funding through the Malta Council for Science and Technology and Malta Enterprise. Results from the Cov-Plex study, which will span over the next 12 months, will be vital for vaccine...